INDIGO: clinical benefit of vorasidenib in patients with grade 2 IDH-mutant glioma

ASCO 2023 highlights in breast cancer: NATALEE, monarchE, and PENELOPE-B

LUNAR: Tumor Treating Field (TTFields) therapy with SOC in mNSCLC following platinum failure

Optimizing first line treatment in metastatic pancreatic cancer

INDIGO: clinical benefit of vorasidenib in patients with grade 2 IDH-mutant glioma

Breast cancer at ASCO 2023: NATALEE and sequencing ADCs

Precision medicine for metastatic triple-negative breast cancer

Current treatment landscape for patients with advanced gastrointestinal stromal tumor (GIST)

PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC

What are the latest developments in KRAS-mutant NSCLC?

PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting

STARTAR: ADT with apalutamide, radiation therapy and docetaxel in prostate cancer

Optimizing outcomes in PSA recurrent prostate cancer

The case for separating G12D mutations in studying KRAS-mutant PDAC

What to look forward to in breast cancer at ASCO 2023

HER2DX risk-score in early-stage HER2-positive breast cancer

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies

Management of brain metastases associated with lung cancer

Targeted therapies in metastatic colorectal cancer

Enhancing the efficacy of immunotherapy in prostate cancer

Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC

Biomarker analyses of the CheckMate 649 trial in GC/GEJC/EAC

Developing targeted therapies for soft tissue sarcomas

An introduction to chondrosarcoma

The potential impact of lifileucel on the treatment landscape of melanoma